Drug development for Autism Spectrum Disorder (ASD): Progress, challenges, and future directions

In 2017, facing lack of progress and failures encountered in targeted drug development for Autism Spectrum Disorder and related neurodevelopmental disorders, the ISCTM with the ECNP created the ASD Working Group charged to identify barriers to progress and recommending research strategies for the field to gain traction

James T. McCracken; Evdokia Anagnostou; Celso Arango; Geraldine Dawson; Tiffany Farchione; Valentina Mantua; James McPartland; Declan Murphy; Gahan Pandina; Jeremy Veenstra-VanderWeele

2021

Scholarcy highlights

  • In 2017, facing lack of progress and failures encountered in targeted drug development for Autism Spectrum Disorder and related neurodevelopmental disorders, the ISCTM with the ECNP created the ASD Working Group charged to identify barriers to progress and recommending research strategies for the field to gain traction
  • Working Group international academic, regulatory and industry representatives held multiple in-person meetings, teleconferences, and subgroup communications to gather a wide range of perspectives on lessons learned from extant studies, current challenges, and paths for fundamental advances in ASD therapeutics
  • Recommendations include new priorities for expanded research funding to overcome challenges in translational clinical Autism Spectrum Disorder therapeutic research

Need more features? Save interactive summary cards to your Scholarcy Library.